3Fine MJ. Risk stratification for patients with community-acquired pneumonia[ J ]. Int J Clin Pract Suppl,2000,115 : 14 - 17.
4Buising KL,Thursky KA, Black JF,et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia:reconsidering what is meant by severe pneumonia[J]. Thorax,2006,61:419 -424.
5Renaud B, Coma E, Labarere J, et al. Routine use of the pneumonia severity index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department [ J ]. Clin Infect Dis,2007,44:41 -49.
6Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults [ J]. Clinical Infectious Diseases,2007,44 :S27 - S72.
7Yah MS, Lee N, lp M, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong[ J 1. Thorax,2007,62:348 - 353.
8Hervier B,Pagnoux C,Agard C,et al.Pulmonary fibrosis associated with ANCA-positive vasculitides.Retrospective study of 12 cases and review of literature[J].Ann Rheum Dis,2009,68(3):404 -407.
9Vasiliauskiene L,Wiik A,Hφier-Madsen M.Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis[J].Ann Rheum Dis,2001,60(5):459-466.
10Pradhan VD,Badakere SS,Bichile LS,et al.Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus:prevalence,clinical associations and correlation with other autoantibodies[J].J Assoc Physicians India,2004,52:533 -537.
